FDA Guaifenesin Crackdown Based On Adams Labs NDA “Improper” – Petition
This article was originally published in The Tan Sheet
Executive Summary
FDA's call for the immediate removal of unapproved guaifenesin extended-release drugs from the market "improperly cedes FDA's enforcement discretion to private parties," four law firms maintain in a Nov. 12 citizen petition
You may also be interested in...
FDA Unapproved Drug Draft Compliance Policy Allows One-Year Grace Period
FDA intends to permit a one-year grace period before taking enforcement action against firms marketing unapproved drugs following the approval of a drug of the same type under a new drug application, according to a draft 1compliance policy guide published in the Oct. 23 Federal Register
FDA Unapproved Drug Draft Compliance Policy Allows One-Year Grace Period
FDA intends to permit a one-year grace period before taking enforcement action against firms marketing unapproved drugs following the approval of a drug of the same type under a new drug application, according to a draft 1compliance policy guide published in the Oct. 23 Federal Register
FDA Unapproved Drug Draft Compliance Policy Allows One-Year Grace Period
FDA intends to permit a one-year grace period before taking enforcement action against firms marketing unapproved drugs following the approval of a drug of the same type under a new drug application, according to a draft 1compliance policy guide published in the Oct. 23 Federal Register